RP155PM-Scl-10CENPBPM-Scl-75systemic sclerosisSSccoronary artery disease
… p=0.007) and Ku antibodies (60% vs. 6.67%; p<0.001). Moreover, RP155 positivity was significantly associated with a higher frequency…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 61–120 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Upadacitinib39NT-proBNP38Nintedanib38Tacrolimus38Levobupivacaine38Warfarin37Mycophenolate37Durvalumab36IVIG36PrEP35Ustekinumab35Levetiracetam34Alcohol34MMF33Azithromycin33Acetaminophen33Dupilumab32Gemcitabine32Steroids32Glucagon-like peptide-1 receptor agonists32Ursodeoxycholic Acid32Linezolid31Ticagrelor30Ezetimibe30Epinephrine30Furosemide30Amoxicillin30Remifentanil30Apixaban30Doxorubicin29Colchicine28Oxycodone28UDCA28ICS28Antidepressants28Atorvastatin27Trastuzumab27Tranexamic Acid27meropenem27Rivaroxaban27Beta-blockers27Metronidazole27Aflibercept26HCQ26Capecitabine26Gabapentin26Corticosteroid26Clonidine26Heparin26Medication26GLP-1RA25Methadone25IL-225Onyx25Ocrelizumab24Amiodarone24Local anesthetic24sufentanil24medications24GLP-1RAs23
Articles mentioning drugs
10,506 articles · page 335 of 876mycophenolate mofetilnifedipinemethotrexatemycophenolic acidpulmonary hypertensionlymphocytic myocarditisSystemic sclerosispolymyositis
…with intravenous cyclophosphamide (cumulative 6 g), followed by mycophenolate mofetil (2 g/day), leading to initial clinical and laboratory improveme…
rituximabTNF-alfaTNF-alfa inhibitorsSystemic sclerosis (SSc)pulmonary arterial hypertensionMSCTpulmonary fibrosis
… dose glucocorticoids and immunosuppressants, 45 (68%) received rituximab (RTM) at cumulative dose 2.4±1.5 grams. The level of TNF-alpha …
calcium channel blockers5-phosphodiesterase inhibitorsprostacyclin analogsendothelin-receptor antagonistsSScsystemic sclerosissRPpRP
…esterase inhibitors were excluded. Other vasoactive treatments (calcium channel blockers) were stopped two days before the experiments. Forty-two female…
mophetil micofenolateMTXmethotrexateGaslini HospitalJuvenile Localized cutaneous scleroderma (JLS)Rheumatology Unit
… MTX therapy was documented in 2 patients, who were switched to mophetil micofenolate. A concordance between mLOSSI, IRT and US was found in 5 cases …
ScleroIDsystemic sclerosisSclerodermaskin fibrosisSScScleroID
…nced by other factors. Further research is required to validate ScleroID as a potential PROM for assessing the impact of skin fibrosis o…
hydroxychloroquinemethotrexatecyclosporinetacrolimusmorpheaSjögren’s diseaseHashimoto thyroiditisCrohn’s diseaseerythema nodosumtype 1 diabetes+1 more
….4% of patients) whereas systemic agents, such as methotrexate, hydroxychloroquine, steroids and cyclosporine (in 38.6% of patients), were reserve…
YKL-40GDF-15S100A8/A9SScischemic heart diseaseinterstitial lung diseaseILD
…cal significance. Finally, PC4, marked by positive contribution YKL-40 and TIMP-1, and negative from MMP-9, was associated with perica…
Myriad RBMCCL2CCL8CCL19systemic sclerosis (SSc)dcSScEudraCTSSctargeted therapies
…concentrations of CCL2, CCL8, CCL19, CXCL9, CXCL10, and CXCL11 (Myriad RBM) in patients with systemic sclerosis (SSc) fulfilling the 2013 …
prednisolonerituximabcyclophosphamidea-topo-1systemic sclerosissystemic sclerosis (SSc)Skin fibrosisinterstitial lung disease (ILD)ILDRTX therapy
… mean disease duration was 6.3±4.9 years. All patients received prednisolone at mean dose of 10.5±4.2 mg/day. 10% of patients received cyclo…
bosentancyclophosphamideSystemic SclerosisNCT05168215SScCURE
…d EUSTAR activity index in Greek patients with SSc treated with bosentan over 18 months.…
bosentanSystemic sclerosis (SSc)CURENCT05168215SSc
…on in the number of DUs in Greek patients with SSc treated with bosentan for 18 months.…